Compound ID | 512
WQ-3335
Class: Fluoroquinolone
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | This had high bioavailability in rats and dogs with no cutaneous phototoxicity in mice. In comparison to ciprofloxacin, levofloxacin, gatifloxacin and moxifloxacin , it was more potent when tested against S. pneumoniae. |
| Description: | Amano H, Ohsita Y, Hayashi N, Amago T, Takenaka H, Tamura K, et al. WQ-3335, a novel fluoroquinolone with enhanced activity against QRSP. 45th-Intersci-Conf-Antimicrob-Agents-Chemother 2005;185 |
| Institute where first reported: | Wakunaga Pharmaceutical Co., Ltd., Japan |
| Year first mentioned: | 2005 |
| Highest developmental phase: | Preclinical |
| Development status: | Inactive |
| Reason Dropped: | There has not been any report of this entering clinical trials, in 2006 it was offered up for worldwide licensing. This is likely to have been dropped through no investment (2). |
| External links: | |
| Citations: |
|
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.